A new solution for children's "digital stress eye strain":
Rohto Eye Vision, now available, featuring Japan's only *1 BTA formula that focuses on inflammation of children's eyes.
March 26, 2026
ROHTO Pharmaceutical Co., Ltd. (Headquarters: Osaka City, President: Hidetoshi Segi) will launch "Rohto Eye Vision," a children's eye drop that focuses on "eye strain caused by digital stress *2" in children due to the use of digital devices such as smartphones and tablets, on Thursday, March 26, 2026.
Our unique "BTA formula (berberine chloride hydrate, taurine, sodium azulene sulfonate hydrate)" provides comprehensive care for "inflammation of the eye surface" that is common when using digital devices. This product is designed to support the recovery of your child's visual abilities.
*1: Survey conducted as of March 2025, based on the PMDA website's search function for over-the-counter and prescription-only drugs, and the JAPIC Over-the-Counter Drug Compendium 2025.
*2: Refers to excessive use of digital devices, etc.
Product launch background
The digital environment surrounding children today is rapidly expanding. According to a survey by the Agency for Children and Families, internet use among children, including younger children, is widespread, with approximately 90% of elementary school students (6-9 years old) using the internet. *3
Furthermore, the smartphone usage rate among elementary school students aged 10 and over expanded from 49.8% to 66.7% between fiscal years 2019 and 2024, and the usage rate of computers and tablets (GIGA terminals) distributed or designated by schools also increased significantly from 50% in the 2021 survey to 75.9%. *3
The use of digital devices tends to increase with age, with elementary school students aged 10 and over averaging approximately 3 hours and 44 minutes of use per day, indicating that digital contact increases significantly as children progress through school age. *3 In addition, for smartphones, the ratio of dedicated to shared use reverses at age 10, with the proportion of children-only devices exceeding 65%, showing that not only the usage time but also the usage environment itself is changing. * 3
The use of digital devices is no longer a temporary trend, but has become an integral part of learning and daily life. However, the strain on the eyes and the impact on visual function due to prolonged use have emerged as a health issue that society as a whole must address. While concern about the progression of myopia is growing, the current situation is that concrete measures to protect children's eye health are insufficient.
In particular, using digital devices can easily cause inflammation of the eye surface due to reduced blinking, which is one of the causes of eye strain. However, conventional children's eye drops mainly address symptoms such as itching and redness, and there have been few products that focus on eye strain caused by digital stress.
Our company has consistently addressed issues related to visual function through research and awareness campaigns on children's eye health, initiatives in the device field, and collaborative projects with local governments. In today's world, where coexistence with digital devices is a given, protecting children's visual abilities is a crucial social issue. Against this backdrop, we developed this product as a new care option that focuses on digital stress.
*3: (Source) Agency for Children and Families, FY2024 Survey on the Actual State of Internet Use Environment for Young People
Product features
Japan's only *1 BTA prescription that focuses on the "inflammatory symptoms" that cause digital fatigue.
Rohto's unique formula combines berberine chloride hydrate (B), taurine (T), and sodium azulene sulfonate hydrate (A).
In response to the "inflammation" that causes digital fatigue,
・ restraint: Suppresses the production of inflammatory substances
・ Sedation: To soothe inflammation that has already occurred
We care for your child's eyes from these two perspectives.
Contains ingredients that improve focusing ability and protect the cornea.
Neostigmine methylsulfate addresses fatigue in the focusing muscles.
It contains chondroitin sulfate sodium (corneal protective ingredient).
Can be used from 1 year old / Contains no benzalkonium chloride or parabens as preservatives
Suitable for use by young children aged 1 year and older, it supports self-care for people of all ages suffering from symptoms.
Product overview
| Product name |
Rohto iVision |
| image |
 |
| classification |
Category 3 drugs |
| Sales name |
Rohto iVision |
| capacity |
13ml |
| price |
800 yen (excluding tax) |
| component |
● Berberine chloride hydrate 0.025% ● Sodium azulene sulfonate hydrate 0.02% ● Taurine 0.1% ● Neostigmine methyl sulfate 0.005% ● Chondroitin sulfate sodium 0.25% *This product contains the following additives: boric acid, borax, sodium edetate, BHT, eucalyptus oil, d-borneol, polysorbate 80, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, povidone, sesame oil, and pH adjusters. |
| Efficacy and effectiveness |
Eye strain, prevention of eye diseases (after swimming, when dust or sweat gets in the eyes, etc.), blurred vision (when there is a lot of eye discharge, etc.), conjunctival congestion, itchy eyes, eye inflammation caused by ultraviolet rays or other light (snow blindness, etc.), blepharitis (inflammation of the eyelids), discomfort while wearing hard contact lenses. |
| Usage/Dosage |
Instill 1-2 drops into each eye 3-4 times a day. |
- "iVision" is a registered trademark of ROHTO Pharmaceutical Co., Ltd.
- "BTA" is a registered trademark of ROHTO Pharmaceutical Co., Ltd.